Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy

Shahrokh F. Shariat, Ganesh S. Palapattu, Gilad E. Amiel, Pierre I. Karakiewicz, Craig G. Rogers, Amnon Vazina, Mark P. Schoenberg, Seth P. Lerner, Arthur I. Sagalowsky, Yair Lotan

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objectives: To describe the cancer-specific outcomes of patients with pathologic carcinoma in situ (CIS) only at radical cystectomy. Methods: The records of 812 consecutive patients who underwent radical cystectomy and pelvic lymphadenectomy for bladder transitional cell carcinoma at three U.S. academic centers were reviewed. Of the 812 patients, 99 (12%) had CIS only at radical cystectomy. Results: The distribution of clinical stage for the 99 patients with CIS only at radical cystectomy was as follows: 47% of patients had CIS only, 8% had cT1, 15% had cT1 plus CIS, 10% had cT2, 13% had cT2 plus CIS, 6% had cTa, and 1% had Ta plus CIS. Two patients had lymphovascular invasion in the radical cystectomy specimen, and three had metastases to the lymph nodes. The actuarial recurrence-free survival estimates were 89.8% (95% confidence interval [CI] 83.0% to 96.6%) at 3 years and 83.0% (95% CI 73.2% to 92.8%) at 5 and 7 years after radical cystectomy. Six patients (6%) had died of bladder cancer at analysis and 13 (13%) had died of other causes without evidence of disease recurrence. The actuarial disease-specific survival estimates were 95.8% (95% CI 91.2% to 99.9%) at 3 years, 90.7% (95% CI 82.4% to 98.9%) at 5 years, and 87.2% (95% CI 76.8% to 97.5%) at 7 years after surgery. On univariate Cox regression analyses, only metastasis to lymph nodes was associated with bladder cancer recurrence and death (P <0.001). Conclusions: Disease control seemed durable for patients with pathologic CIS only at radical cystectomy in the absence of metastases to the lymph nodes, even in the case of failure after intravesical therapy.

Original languageEnglish (US)
Pages (from-to)538-542
Number of pages5
JournalUrology
Volume68
Issue number3
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Cystectomy
Carcinoma in Situ
Confidence Intervals
Lymph Nodes
Neoplasm Metastasis
Urinary Bladder Neoplasms
Recurrence
Hospital Distribution Systems
Survival
Transitional Cell Carcinoma
Lymph Node Excision
Urinary Bladder
Regression Analysis

ASJC Scopus subject areas

  • Urology

Cite this

Shariat, S. F., Palapattu, G. S., Amiel, G. E., Karakiewicz, P. I., Rogers, C. G., Vazina, A., ... Lotan, Y. (2006). Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology, 68(3), 538-542. https://doi.org/10.1016/j.urology.2006.03.033

Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. / Shariat, Shahrokh F.; Palapattu, Ganesh S.; Amiel, Gilad E.; Karakiewicz, Pierre I.; Rogers, Craig G.; Vazina, Amnon; Schoenberg, Mark P.; Lerner, Seth P.; Sagalowsky, Arthur I.; Lotan, Yair.

In: Urology, Vol. 68, No. 3, 09.2006, p. 538-542.

Research output: Contribution to journalArticle

Shariat, SF, Palapattu, GS, Amiel, GE, Karakiewicz, PI, Rogers, CG, Vazina, A, Schoenberg, MP, Lerner, SP, Sagalowsky, AI & Lotan, Y 2006, 'Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy', Urology, vol. 68, no. 3, pp. 538-542. https://doi.org/10.1016/j.urology.2006.03.033
Shariat SF, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A et al. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006 Sep;68(3):538-542. https://doi.org/10.1016/j.urology.2006.03.033
Shariat, Shahrokh F. ; Palapattu, Ganesh S. ; Amiel, Gilad E. ; Karakiewicz, Pierre I. ; Rogers, Craig G. ; Vazina, Amnon ; Schoenberg, Mark P. ; Lerner, Seth P. ; Sagalowsky, Arthur I. ; Lotan, Yair. / Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. In: Urology. 2006 ; Vol. 68, No. 3. pp. 538-542.
@article{670487491bbf45689a4dbdcef460c8ca,
title = "Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy",
abstract = "Objectives: To describe the cancer-specific outcomes of patients with pathologic carcinoma in situ (CIS) only at radical cystectomy. Methods: The records of 812 consecutive patients who underwent radical cystectomy and pelvic lymphadenectomy for bladder transitional cell carcinoma at three U.S. academic centers were reviewed. Of the 812 patients, 99 (12{\%}) had CIS only at radical cystectomy. Results: The distribution of clinical stage for the 99 patients with CIS only at radical cystectomy was as follows: 47{\%} of patients had CIS only, 8{\%} had cT1, 15{\%} had cT1 plus CIS, 10{\%} had cT2, 13{\%} had cT2 plus CIS, 6{\%} had cTa, and 1{\%} had Ta plus CIS. Two patients had lymphovascular invasion in the radical cystectomy specimen, and three had metastases to the lymph nodes. The actuarial recurrence-free survival estimates were 89.8{\%} (95{\%} confidence interval [CI] 83.0{\%} to 96.6{\%}) at 3 years and 83.0{\%} (95{\%} CI 73.2{\%} to 92.8{\%}) at 5 and 7 years after radical cystectomy. Six patients (6{\%}) had died of bladder cancer at analysis and 13 (13{\%}) had died of other causes without evidence of disease recurrence. The actuarial disease-specific survival estimates were 95.8{\%} (95{\%} CI 91.2{\%} to 99.9{\%}) at 3 years, 90.7{\%} (95{\%} CI 82.4{\%} to 98.9{\%}) at 5 years, and 87.2{\%} (95{\%} CI 76.8{\%} to 97.5{\%}) at 7 years after surgery. On univariate Cox regression analyses, only metastasis to lymph nodes was associated with bladder cancer recurrence and death (P <0.001). Conclusions: Disease control seemed durable for patients with pathologic CIS only at radical cystectomy in the absence of metastases to the lymph nodes, even in the case of failure after intravesical therapy.",
author = "Shariat, {Shahrokh F.} and Palapattu, {Ganesh S.} and Amiel, {Gilad E.} and Karakiewicz, {Pierre I.} and Rogers, {Craig G.} and Amnon Vazina and Schoenberg, {Mark P.} and Lerner, {Seth P.} and Sagalowsky, {Arthur I.} and Yair Lotan",
year = "2006",
month = "9",
doi = "10.1016/j.urology.2006.03.033",
language = "English (US)",
volume = "68",
pages = "538--542",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy

AU - Shariat, Shahrokh F.

AU - Palapattu, Ganesh S.

AU - Amiel, Gilad E.

AU - Karakiewicz, Pierre I.

AU - Rogers, Craig G.

AU - Vazina, Amnon

AU - Schoenberg, Mark P.

AU - Lerner, Seth P.

AU - Sagalowsky, Arthur I.

AU - Lotan, Yair

PY - 2006/9

Y1 - 2006/9

N2 - Objectives: To describe the cancer-specific outcomes of patients with pathologic carcinoma in situ (CIS) only at radical cystectomy. Methods: The records of 812 consecutive patients who underwent radical cystectomy and pelvic lymphadenectomy for bladder transitional cell carcinoma at three U.S. academic centers were reviewed. Of the 812 patients, 99 (12%) had CIS only at radical cystectomy. Results: The distribution of clinical stage for the 99 patients with CIS only at radical cystectomy was as follows: 47% of patients had CIS only, 8% had cT1, 15% had cT1 plus CIS, 10% had cT2, 13% had cT2 plus CIS, 6% had cTa, and 1% had Ta plus CIS. Two patients had lymphovascular invasion in the radical cystectomy specimen, and three had metastases to the lymph nodes. The actuarial recurrence-free survival estimates were 89.8% (95% confidence interval [CI] 83.0% to 96.6%) at 3 years and 83.0% (95% CI 73.2% to 92.8%) at 5 and 7 years after radical cystectomy. Six patients (6%) had died of bladder cancer at analysis and 13 (13%) had died of other causes without evidence of disease recurrence. The actuarial disease-specific survival estimates were 95.8% (95% CI 91.2% to 99.9%) at 3 years, 90.7% (95% CI 82.4% to 98.9%) at 5 years, and 87.2% (95% CI 76.8% to 97.5%) at 7 years after surgery. On univariate Cox regression analyses, only metastasis to lymph nodes was associated with bladder cancer recurrence and death (P <0.001). Conclusions: Disease control seemed durable for patients with pathologic CIS only at radical cystectomy in the absence of metastases to the lymph nodes, even in the case of failure after intravesical therapy.

AB - Objectives: To describe the cancer-specific outcomes of patients with pathologic carcinoma in situ (CIS) only at radical cystectomy. Methods: The records of 812 consecutive patients who underwent radical cystectomy and pelvic lymphadenectomy for bladder transitional cell carcinoma at three U.S. academic centers were reviewed. Of the 812 patients, 99 (12%) had CIS only at radical cystectomy. Results: The distribution of clinical stage for the 99 patients with CIS only at radical cystectomy was as follows: 47% of patients had CIS only, 8% had cT1, 15% had cT1 plus CIS, 10% had cT2, 13% had cT2 plus CIS, 6% had cTa, and 1% had Ta plus CIS. Two patients had lymphovascular invasion in the radical cystectomy specimen, and three had metastases to the lymph nodes. The actuarial recurrence-free survival estimates were 89.8% (95% confidence interval [CI] 83.0% to 96.6%) at 3 years and 83.0% (95% CI 73.2% to 92.8%) at 5 and 7 years after radical cystectomy. Six patients (6%) had died of bladder cancer at analysis and 13 (13%) had died of other causes without evidence of disease recurrence. The actuarial disease-specific survival estimates were 95.8% (95% CI 91.2% to 99.9%) at 3 years, 90.7% (95% CI 82.4% to 98.9%) at 5 years, and 87.2% (95% CI 76.8% to 97.5%) at 7 years after surgery. On univariate Cox regression analyses, only metastasis to lymph nodes was associated with bladder cancer recurrence and death (P <0.001). Conclusions: Disease control seemed durable for patients with pathologic CIS only at radical cystectomy in the absence of metastases to the lymph nodes, even in the case of failure after intravesical therapy.

UR - http://www.scopus.com/inward/record.url?scp=33748930612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748930612&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2006.03.033

DO - 10.1016/j.urology.2006.03.033

M3 - Article

VL - 68

SP - 538

EP - 542

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -